Stock Alert: Chimerix (CMRX) Trades 13.73% Higher August 4

Equities Staff  |

Chimerix Inc (NASDAQ:CMRX) stock was among today's market movers, ending trading higher 13.73% to $2.65 on August 4.

12,632,297 shares traded today compared to the 30-day daily average of 6,327,001 shares.

The company's stock has risen 63.76% so far in 2022.

Chimerix shares have traded in a range between $1.27 and $7.42 over the past twelve months.

The company expects its next earnings on 2022-08-04.

For technical charts, analysis, and more on Chimerix visit the company profile.

About Chimerix Inc

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The company's three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.

To get more information on Chimerix Inc and to follow the company's latest updates, you can visit the company's profile page here: Chimerix Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content